Pipeline Insight: Breast Cancer

Content

• Chapter 1 Executive Summary
  • Scope of The Analysis
  • Datamonitor Insight into The Breast Cancer Market
  • Related Reports
  • Upcoming Reports
• Chapter 2 Pipeline Overview and Dynamics
  • Pipeline Overview
  • Products in Late-Phase Development for Breast Cancer
  • Products in Phase Ii Development for Breast Cancer
  • Products in Phase I Development for Breast Cancer
  • Pipeline by Development Phase and Therapy Class
  • Molecular Targeted Therapies Account for over 50% of All Drugs in Development for Breast Cancer
  • Pipeline by Indication
  • Most Trials of Late-Phase Breast Cancer Drugs Are in The Metastatic Setting
  • Pipeline by Company
  • Biotech and Small/Mid Pharma Account for The Majority of Companies with Drugs in Clinical Development for Breast Cancer
  • The Majority of Companies Have A Single Drug in Clinical Development for Breast Cancer
  • The Top Four Companies in Terms of Marketed and Pipeline Drugs for Breast Cancer Are Novartis, Astrazeneca, Roche and Pfizer
  • Novartis
  • Astrazeneca
  • Pfizer
  • Roche
  • Key Metrics
  • Datamonitor Pipeline Assessment Summary
• Chapter 3 Breast Cancer - Market Potential
  • Definition of Breast Cancer
  • Anatomy of The Breast
  • Histology of Breast Cancer
  • Segmentation of Breast Cancer
  • Staging of Breast Cancer
  • Predictive Markers for Breast Cancer
  • Hormone Receptor Status Used to Predict Benefit of Hormonal Therapy
  • Her-2 Status Is A Well-Established Prognostic Factor and Is Used to Make Therapeutic Choices
  • Gene Expression Analysis Will Further Subdivide The Breast Cancer Population
  • Epidemiology of Breast Cancer
  • Incidence of Breast Cancer in The Seven Major Markets
  • Incidence of Female Invasive Breast Cancer Will Total 455,000 in The Seven Major Markets in 2008
  • Age Distribution of Breast Cancer Incidence Rates
  • Mortality
  • Female Mortality from Breast Cancer Will Total 118,000 in The Seven Major Markets in 2008
  • Current Breast Cancer Treatment Options
  • Overview of Drug Therapies Approved for Breast Cancer
  • Cytotoxic Therapies, Endocrine Therapies and Molecular Targeted Therapies Form The Mainstay of Breast Cancer Drug Therapy
  • Treatment Options and Treatment Outcomes by Disease Stage
  • Early Invasive and Locally Advanced Disease Is Treated with Surgery and Adjuvant/Neoadjuvant Therapy
  • Metastatic Breast Cancer Treated with Intention of Improving Quality of Life
  • Unmet Needs in Breast Cancer
  • Agents Capable of Increasing Overall Survival Are Needed for Metastatic Breast Cancer
  • More Treatment Options Are Needed for Hormone Receptor-Negative and Her-2-Negative Patients
  • Treatment Options for Elderly Patients Are Limited by Small Amount of Data
  • More Tolerable and More Convenient Drug Therapies Are Needed
• Chapter 4 R&d Approach
  • Classification of Pipeline Products
  • Cytotoxics
  • Endocrine Therapies
  • Molecular Targeted Therapies
  • Single-Target Signal Transduction Inhibitors
  • Angiogenesis Inhibitors
  • Apoptosis Inducers
  • Cell Cycle Inhibitors
  • Multi-Targeted Inhibitors
  • Epigenetic Modulators
  • Immunotherapeutic Agents
  • Optimizing Clinical Trial Design in Breast Cancer
  • Patient Selection Is Important for Successful Development of Targeted Therapies in Breast Cancer
  • Clinical Trial Endpoints in Breast Cancer
  • Survival: Progression-Free Survival Is Commonly-Used as A Primary Endpoint for Metastatic Breast Cancer
• Chapter 5 Cytotoxic Therapies Analysis and Forecasts
  • Overview of Cytotoxic Therapies
  • Pipeline Summary
  • Late-Phase Pipeline of Cytotoxic Therapies
  • Phase Ii Pipeline of Cytotoxic Therapies
  • Phase I Pipeline of Cytotoxic Therapies
  • Comparative Forecasts
  • Definition of Current Comparator Therapy
  • Taxotere (Docetaxel; Sanofi-Aventis)
  • Eribulin (E7389; Eisai)
  • Drug Overview
  • Key Historical Events
  • Clinical Development in Breast Cancer
  • Two Phase Iii Studies Are to Evaluate Eribulin in Relapsed Locally Advanced and Metastatic Breast Cancer
  • Phase Ii Results Show Some Activity and Relatively Low Toxicity in A Heavily Pretreated Refractory Breast Cancer Patient Population
  • Datamonitor Comments
  • Eribulin Will Need to Demonstrate Considerable Efficacy or Toxicity Benefits in The Face of Strong Competition
  • Eisai Could Benefit from Help of Company with More Experience of The Breast Cancer Market
  • Forecasts to 2017
  • Larotaxel (Xrp-9881; Sanofi-Aventis)
  • Drug Overview
  • Key Historical Events
  • Clinical Development in Breast Cancer
  • Phase Iii Trial Shows That Larotaxel Has No Superiority over Xeloda in Terms of Response Rate in Progressive Metastatic Breast Cancer
  • Larotaxel Confers A 19% Response Rate in Taxane-Resistant Metastatic Breast Cancer in A Phase Ii Study
  • Earlier Phase Ii Results Show Larotaxel Confers Greater Activity in Taxane Non-Resistant Patients, but at The Expense of High Toxicity
  • Datamonitor Comments
  • Failure to Show Superiority over Xeloda Has Dented Prospects of Larotaxel as A Single Agent
  • Too Early to Predict Clinical Potential of Combinations of Larotaxel
  • Genericization of Taxanes Will Further Limit Larotaxel's Commercial Potential
• Chapter 6 Endocrine Therapies Analysis and Forecasts
  • Overview of Endocrine Therapies
  • Pipeline Summary
  • Late-Phase Pipeline of Endocrine Therapies
  • Phase Ii Pipeline of Endocrine Therapies
  • Phase I Pipeline of Endocrine Therapies
  • Arzoxifene (Ly-353381; Eli Lilly)
  • Drug Overview
  • Key Historical Events
  • Clinical Development in Breast Cancer
  • Arzoxifene Has Inferior Efficacy to Tamoxifen in Phase Iii Study
  • Datamonitor Comments
  • Disappointing Phase Iii Trial Results Mean That Arzoxifene Is Unlikely to Reach The Market as A Breast Cancer Treatment
• Chapter 7 Molecular Targeted Therapies Analysis and Forecasts
  • Overview of Molecular Targeted Therapies
  • Pipeline Summary
  • Late-Phase Pipeline of Molecular Targeted Therapies
  • Phase Ii Pipeline of Molecular Targeted Therapies
  • Phase I Pipeline of Molecular Targeted Therapies
  • Comparative Forecasts
  • Definition of Current Comparator Therapy
  • Herceptin (Trastuzumab; Genentech/Roche/Chugai)
  • Armala (Pazopanib; Glaxosmithkline)
  • Drug Overview
  • Key Historical Events
  • Clinical Development in Breast Cancer
  • Phase Iii Study Will Evaluate Combination of Armala and Tykerb as A Second-Line Therapy in Her-2-Positive Inflammatory Breast Cancer Patients
  • Datamonitor Comments
  • Armala Could Satisfy Significant Unmet Need in Inflammatory Breast Cancer, but This Indication Has A Very Limited Patient Potential
  • Lack of Phase Ii Data Makes IT Difficult to Comment on Activity of Armala in Breast Cancer
  • The Combination of Armala and Tykerb Could Be Too Costly for Some Healthcare Markets
  • Forecasts to 2017
  • Certican (Everolimus, Rad-001; Novartis)
  • Drug Overview
  • Key Historical Events
  • Clinical Development in Breast Cancer
  • Phase Iii Study Will Evaluate Certican and Paclitaxel as One of Six Regimens in The Neoadjuvant Setting
  • Combination of Certican and Femara Shows Promise in The Neoadjuvant Setting for Er-Positive Breast Cancer
  • Early Phase Ii Data Show That Certican Has Some Activity as A Single Agent in Metastatic Breast Cancer
  • Datamonitor Comments
  • Certican Will Have to Significantly Improve Treatment Outcomes in Order to Ensure Uptake in The Neoadjuvant Setting
  • Limited Amount of Phase Ii Data Makes IT Difficult to Assess Clinical Potential of Certican in Metastatic Breast Cancer
  • Novartis's Oncology Marketing Presence and Experience of The Breast Cancer Market Will Increase Certican's Chances of Success
  • Forecasts to 2017
  • Omnitarg (Pertuzumab; Genentech/Roche/Chugai)
  • Drug Overview
  • Key Historical Events
  • Clinical Development in Breast Cancer
  • Phase Iii Study Is Evaluating The Combination of Omnitarg, Herceptin and Taxotere as A First-Line Treatment for Her-2-Positive Metastatic Breast Cancer
  • Phase Ii Study Suggests That Combination of Herceptin plus Omnitarg Has Activity in Progressive Metastatic Breast Cancer Previously Treated with Herceptin
  • Omnitarg Has Limited Activity as A Single Agent in Metastatic Breast Cancer with Low Her-2 Expression
  • Datamonitor Comments
  • Clinical Benefit Will Have to Outweigh Increased Cost of Adding Omnitarg to Herceptin
  • Uncertain Whether Omnitarg Will Be Developed for Her-2-Negative Population
  • Forecasts to 2017
  • Sutent (Sunitinib; Pfizer)
  • Drug Overview
  • Key Historical Events
  • Clinical Development in Breast Cancer
  • Extensive Development Program Shows Pfizer's Bold Ambitions for Sutent in The Breast Cancer Market
  • Four Ongoing Phase Iii Trials Are Evaluating Sutent as A Treatment for Metastatic Breast Cancer
  • Single-Agent Sutent Is Active in Heavily Pretreated Metastatic Breast Cancer Patients
  • Datamonitor Comments
  • Sutent Will Compete with Avastin in The Her-2-Negative Metastatic Breast Cancer Population
  • Sutent Could Have A Competitive Edge over Other Small-Molecule Targeted Therapies in The Late-Phase Breast Cancer Pipeline
  • Forecasts to 2017
  • Axitinib (Ag-013736; Pfizer)
  • Drug Overview
  • Key Historical Events
  • Clinical Development in Breast Cancer
  • Randomized Phase Ii Trial Suggests Combination of Axitinib and Taxotere Has Promising Efficacy in Metastatic Breast Cancer
  • Datamonitor Comments
  • Axitinib Could Struggle to Compete against Avastin but May Have Significant Potential in Subset of Patients Previously Treated with Adjuvant Therapy
  • Pfizer Appears to Be Prioritizing The Development of Sutent over The Development of Axitinib in Breast Cancer
• Chapter 8 Immunotherapies and Gene Therapies
  • Overview of Immunotherapies and Gene Therapies
  • Pipeline Summary
  • Phase Ii Pipeline of Immunotherapies and Gene Therapies
  • Phase I Pipeline Immunotherapies Therapies
• Appendix
  • Bibliography
  • List of Figures
  • List of Abbreviations
  • Methodology
  • Datamonitor Forecast Methodology
  • Epidemiology Forecasts
  • Product Forecasts
  • about Datamonitor
  • about Datamonitor Healthcare
  • Datamonitor Healthcare's Therapy Area Capabilities
  • about The Disease Analysis Team
  • Disclaimer
• List of Tables
  • Table 1: Late-Phase Pipeline for Breast Cancer, 2008
  • Table 2: Phase Ii Pipeline for Breast Cancer, 2008
  • Table 3: Phase I Pipeline for Breast Cancer, 2008
  • Table 4: Number of Pipeline Drugs for Breast Cancer by Therapy Class and Phase of Development, 2008
  • Table 5: Treatment Settings under Investigation in Ongoing Phase I-Iii Clinical Trials of Drugs in Late-Phase Development for Breast Cancer, 2008
  • Table 6: Companies with Three or More Drugs in Clinical Development for Breast Cancer, 2008
  • Table 7: Novartis's Marketed Cancer Portfolio, 2008
  • Table 8: Novartis's Portfolio of Marketed and Pipeline Drugs for Breast Cancer, 2008
  • Table 9: Astrazeneca's Marketed Cancer Portfolio, 2008
  • Table 10: Astrazeneca's Portfolio of Marketed and Pipeline Drugs for Breast Cancer, 2008
  • Table 11: Pfizer's Marketed Cancer Portfolio, 2008
  • Table 12: Pfizer's Portfolio of Marketed and Pipeline Drugs for Breast Cancer, 2008
  • Table 13: Roche's Marketed Oncology Portfolio, 2008
  • Table 14: Roche's Portfolio of Marketed and Pipeline Drugs for Breast Cancer, 2008
  • Table 15: Late-Phase Breast Cancer Products Sales Forecasts in The Seven Major Markets ($M), 2008-2017
  • Table 16: Crude Female Invasive Breast Cancer Incidence Rates (per 100,000 Persons) in The Seven Major Markets, 2002
  • Table 17: Forecast Incidence of Invasive Female Breast Cancer in The Seven Major Markets, 2002-17
  • Table 18: Crude Female Breast Cancer Mortality Rates (per 100,000 Persons) in The Seven Major Markets, 2002
  • Table 19: Forecast Mortality from Breast Cancer in The Seven Major Markets, 2002 and 2008
  • Table 20: Approved Cytotoxic Therapies for Breast Cancer in The Seven Major Markets, March 2008
  • Table 21: Approved Endocrine Therapies for Breast Cancer in The Seven Major Markets, March 2008
  • Table 22: Approved Molecular Targeted Therapies for Breast Cancer in The Seven Major Markets, March 2008
  • Table 23: Summary of Treatment Outcomes for Adjuvant Drug Regimens in Stage I-Iii Breast Cancer
  • Table 24: Summary of Treatment Outcomes for Neoadjuvant Drug Regimens in Stage I-Iii Breast Cancer
  • Table 25: Summary of Treatment Outcomes for Drug Regimens in Stage Iv Breast Cancer
  • Table 26: Late-Phase Pipeline Cytotoxic Therapies in Breast Cancer, 2008
  • Table 27: Phase Ii Pipeline Cytotoxic Therapies in Breast Cancer, 2008
  • Table 28: Phase I Pipeline Cytotoxic Therapies in Breast Cancer, 2008
  • Table 29: Forecasting Assumptions for Late-Phase Cytotoxic Therapies in The Seven Major Pharmaceutical Markets, 2008
  • Table 30: Taxotere: Key Facts
  • Table 31: Eribulin: Key Historical Events
  • Table 32: Ongoing Clinical Trials Involving Eribulin in Breast Cancer, 2008
  • Table 33: Eisai's Oncology Portfolio, 2008
  • Table 34: Forecasting Assumptions for Eribulin in The Seven Major Pharmaceutical Markets, 2008 (1 of 2)
  • Table 35: Forecasting Assumptions for Eribulin in The Seven Major Pharmaceutical Markets, 2008 (2 of 2)
  • Table 36: Eribulin Sales Forecast for Third-Line Therapy in Locally Recurrent and Metastatic Breast Cancer in The Seven Major Pharmaceutical Markets ($M), 2008-2017
  • Table 37: Larotaxel: Key Historical Events
  • Table 38: Ongoing Clinical Trials Involving Larotaxel in Breast Cancer, 2008
  • Table 39: Late-Phase Endocrine Therapies in Breast Cancer, 2008
  • Table 40: Phase Ii Endocrine Therapies in Breast Cancer, 2008
  • Table 41: Phase I Endocrine Therapies in Breast Cancer, 2008
  • Table 42: Arzoxifene: Key Historical Events
  • Table 43: Late-Phase Molecular Targeted Therapies in Breast Cancer, 2008
  • Table 44: Phase Ii Molecular Targeted Therapies in Breast Cancer, 2008
  • Table 45: Phase I Molecular Targeted Therapies in Breast Cancer, 2008
  • Table 46: Forecasting Assumptions for Mtts in The Seven Major Pharmaceutical Markets, 2008 (1 of 2)
  • Table 47: Forecasting Assumptions for Mtts in The Seven Major Pharmaceutical Markets, 2008 (2 of 2)
  • Table 48: Herceptin: Key Facts
  • Table 49: Armala: Key Historical Events
  • Table 50: Ongoing Clinical Trials Involving Armala in Breast Cancer, 2008
  • Table 51: Forecasting Assumptions for Armala in The Seven Major Pharmaceutical Markets, 2008 (1 of 2)
  • Table 52: Forecasting Assumptions for Armala in The Seven Major Pharmaceutical Markets, 2008 (2 of 2)
  • Table 53: Armala Sales Forecast in Second-Line, Her-2-Positive Inflammatory Breast Cancer in The Seven Major Pharmaceutical Markets ($M), 2008-2017
  • Table 54: Certican: Key Historical Events
  • Table 55: Ongoing Clinical Trials Involving Certican in Breast Cancer, 2008
  • Table 56: Forecasting Assumptions for Certican in The Seven Major Pharmaceutical Markets, 2008 (1 of 2)
  • Table 57: Forecasting Assumptions for Certican in The Seven Major Pharmaceutical Markets, 2008 (2 of 2)
  • Table 58: Certican Sales Forecast for Neoadjuvant Therapy in Stage I-Iii Breast Cancer in The Seven Major Pharmaceutical Markets ($M), 2008-2017
  • Table 59: Omnitarg: Key Historical Events
  • Table 60: Ongoing Clinical Trials Involving Omnitarg in Breast Cancer, 2008
  • Table 61: Forecasting Assumptions for Omnitarg in The Seven Major Pharmaceutical Markets, 2008 (1 of 2)
  • Table 62: Forecasting Assumptions for Omnitarg in The Seven Major Pharmaceutical Markets, 2008 (2 of 2)
  • Table 63: Omnitarg Sales Forecast for First-Line Therapy in Her-2-Positive Metastatic Breast Cancer in The Seven Major Pharmaceutical Markets ($M), 2008-2017
  • Table 64: Sutent: Key Historical Events
  • Table 65: Ongoing Clinical Trials Involving Sutent in Breast Cancer, 2008
  • Table 66: Forecasting Assumptions for Sutent in The Seven Major Pharmaceutical Markets, 2008 (1 of 2)
  • Table 67: Forecasting Assumptions for Sutent in The Seven Major Pharmaceutical Markets, 2008 (2 of 2)
  • Table 68: Sutent Sales Forecast for Metastatic and Advanced Breast Cancer in The Seven Major Pharmaceutical Markets ($M), 2008-2017
  • Table 69: Axitinib: Key Historical Events
  • Table 70: Phase Ii Immunotherapies and Gene Therapies in Breast Cancer, 2008
  • Table 71: Phase I Immunotherapies and Gene Therapies in Breast Cancer, 2008
  • Table 72: Abbreviations Used in Pipeline Insight: Breast Cancer
  • Table 73: Datamonitor Drug Assessment Parameters
• List of Figures
  • Figure 1: Number of Pipeline Drugs for Breast Cancer by Therapy Class and Phase of Development, 2008
  • Figure 2: Treatment Settings under Investigation in Ongoing Clinical Trials of Drugs in Late-Phase Development, 2008
  • Figure 3: Breast Cancer Pipeline by Type of Company, 2008
  • Figure 4: Segmentation of Companies According to Number of Drugs in Breast Cancer Pipeline, 2008
  • Figure 5: Companies with Three or More Drugs in Clinical Development for Breast Cancer, 2008
  • Figure 6: Number of Marketed and Pipeline Drugs for Breast Cancer by Stage of Development for Novartis, Astrazeneca, Roche and Pfizer, 2008
  • Figure 7: Late-Phase Breast Cancer Products Sales Forecasts in The Seven Major Markets ($M), 2008-2017
  • Figure 8: Clinical and Commercial Attractiveness of Late-Phase Cytotoxic Therapies in Breast Cancer, 2008
  • Figure 9: Clinical and Commercial Attractiveness of Late-Phase Molecular Targeted Therapies in Breast Cancer, 2008
  • Figure 10: The Human Female Breast
  • Figure 11: Histological Classification of Breast Cancer
  • Figure 12: Definitions Used for Breast Cancer Classification with Tnm Staging System
  • Figure 13: Tnm Staging System for Breast Cancer
  • Figure 14: Molecular Biomarkers Used in Breast Cancer
  • Figure 15: Forecast Incidence of Invasive Female Breast Cancer in The Seven Major Markets, 2002-2017
  • Figure 16: Distribution of Breast Cancer Incidence Rates by Age Group, US, 2000-04
  • Figure 17: Forecast Mortality from Breast Cancer in The Seven Major Markets, 2002 and 2008
  • Figure 18: Summary of Unmet Needs in The Breast Cancer Market, 2008
  • Figure 19: Clinical and Commercial Attractiveness of Late-Phase Cytotoxic Therapies in Breast Cancer, 2008
  • Figure 20: Late-Phase Cytotoxic Therapies Sales Forecasts in Breast Cancer in The Seven Major Markets ($M), 2008-2017
  • Figure 21: Phase Iii Trial Evaluating Eribulin Versus Xeloda in Recurrent Locally Advanced or Metastatic Breast Cancer
  • Figure 22: Embrace Phase Iii Trial Evaluating Eribulin Versus Investigators' Choice of Therapy in Recurrent Locally Advanced or Metastatic Breast Cancer
  • Figure 23: Phase Ii Results for Eribulin Monotherapy in Chemotherapy-Refractory Advanced Breast Cancer Patients
  • Figure 24: Eribulin Sales Forecast for Third-Line Therapy in Locally Recurrent and Metastatic Breast Cancer in The Seven Major Pharmaceutical Markets ($M), 2008-2017
  • Figure 25: Phase Iii Trial Comparing Larotaxel to Xeloda in Progressing Metastatic Breast Cancer
  • Figure 26: Phase Ii Study Investigating Larotaxel in Previously Treated Metastatic Breast Cancer
  • Figure 27: Phase Iii Trial Comparing Arzoxifene to Tamoxifen for Locally Advanced or Metastatic Breast Cancer
  • Figure 28: Clinical and Commercial Attractiveness of Late-Phase Molecular Targeted Therapies in Breast Cancer, 2008
  • Figure 29: Late-Phase Molecular Targeted Therapies Sales Forecasts in Breast Cancer in The Seven Major Markets ($M), 2008-2017
  • Figure 30: Phase Iii Trial Evaluating Armala and Tykerb in Her-2-Positive Inflammatory Breast Cancer
  • Figure 31: Armala Sales Forecast in Second-Line, Her-2-Positive Inflammatory Breast Cancer in The Seven Major Pharmaceutical Markets ($M), 2008-2017
  • Figure 32: Phase Iii Trial of Certican, Avastin and Tykerb in The Neoadjuvant Setting
  • Figure 33: Results of Phase Ii Trial of Certican plus Femara as A Neoadjuvant Breast Cancer Therapy
  • Figure 34: Results of Phase Ii Study of Certican Monotherapy in Metastatic Breast Cancer
  • Figure 35: Certican Sales Forecast for Neoadjuvant Therapy in Stage I-Iii Breast Cancer in The Seven Major Pharmaceutical Markets ($M), 2008-2017
  • Figure 36: Phase Iii Study of Omnitarg plus Herceptin plus Taxotere in Her-2-Positive Metastatic Breast Cancer
  • Figure 37: Phase Ii Results for Omnitarg plus Herceptin in Progressive Her-2-Positive Metastatic Breast Cancer
  • Figure 38: Phase Ii Results of Omnitarg Monotherapy in Previously Treated Metastatic Breast Cancer Patients with Low Her-2 Expression
  • Figure 39: Omnitarg Sales Forecast for First-Line Therapy in Her-2-Positive Metastatic Breast Cancer in The Seven Major Pharmaceutical Markets ($M), 2008-2017
  • Figure 40: Phase Iii Trial of Sutent plus Paclitaxel in First-Line Her-2-Negative Metastatic Breast Cancer
  • Figure 41: Phase Iii Trial of Sutent plus Taxotere in Locally Recurrent or Metastatic Breast Cancer
  • Figure 42: Phase Iii Trial of Sutent plus Xeloda in Locally Advanced or Metastatic Breast Cancer
  • Figure 43: Phase Iii Trial of Single-Agent Sutent in Second-Line Locally Recurrent or Metastatic Breast Cancer
  • Figure 44: Phase Ii Results of Sutent Monotherapy in Progressive Metastatic Breast Cancer
  • Figure 45: Sutent Sales Forecast for Metastatic and Advanced Breast Cancer in The Seven Major Pharmaceutical Markets ($M), 2008-2017
  • Figure 46: Results of Randomized Phase Ii Study of Axitinib plus Taxotere in Metastatic Breast Cancer
  • Figure 47: Datamonitor Drug Assessment Summary of Pipeline Molecular Targeted Therapies in Development for Hematological Malignancies, 2007